CNTX (STOCKS)
Context Therapeutics Inc. Common Stock
$2.450000
-0.040000 (-1.61%)
Prev close: $2.490000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Martin A. Lehr
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $226.02M
- Employees
- 9
- P/E (TTM)
- -6.40
- P/B (TTM)
- 3.78
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.14 | $-0.11 | -0.0318 | -29.39% |
|
Sep 2025 (Q3)
|
$-0.10 | $-0.10 | -0.0039 | -4.06% |
|
Jun 2025 (Q2)
|
$-0.09 | $-0.06 | -0.0276 | -44.23% |
|
Mar 2025 (Q1)
|
$-0.05 | $-0.06 | +0.0090 | +15.25% |
Financial Statements
| Operating Income/Loss | -$39.70M |
| Income/Loss From Continuing Operations After Tax | -$36.12M |
| Income/Loss From Continuing Operations Before Tax | -$36.12M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$36.12M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$36.12M |
| Net Income/Loss Available To Common Stockholders, Basic | -$36.12M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.38 |
| Diluted Earnings Per Share | -$0.38 |
| Basic Average Shares | 95,185,683 |
| Diluted Average Shares | 95,185,683 |
| Assets | $68.49M |
| Current Assets | $68.35M |
| Noncurrent Assets | $140.07K |
| Fixed Assets | $29.66K |
| Other Non-current Assets | $110.41K |
| Liabilities | $8.02M |
| Current Liabilities | $8.02M |
| Accounts Payable | $2.53M |
| Wages | $1.38M |
| Other Current Liabilities | $4.10M |
| Noncurrent Liabilities | $0.00 |
| Equity | $60.47M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $60.47M |
| Liabilities And Equity | $68.49M |
| Net Cash Flow From Operating Activities | -$26.39M |
| Net Cash Flow From Operating Activities, Continuing | -$26.39M |
| Net Cash Flow From Investing Activities | -$2.03M |
| Net Cash Flow From Investing Activities, Continuing | -$2.03M |
| Net Cash Flow From Financing Activities | -$15.27K |
| Net Cash Flow From Financing Activities, Continuing | -$15.27K |
| Net Cash Flow | -$28.43M |
| Net Cash Flow, Continuing | -$28.43M |
| Comprehensive Income/Loss | -$36.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$36.12M |
| Other Comprehensive Income/Loss | $0.00 |